Abstract
Obesity is an outcome of multiple factors including environmental and genetic influences. Common obesity is a polygenic trait indicating that multiple genetic variants act synergistically to influence its expression. We constructed a genetic risk score (GRS) based on five genetic variants (MC4R rs17782313, BDNF rs6265, FTO rs1421085, TMEM18 rs7561317, and NEGR1 rs2815752) and examined its association with obesity-related traits in a sample of Pakistanis. The study involved 306 overweight/obese (OW/OB) and 300 normal-weight (NW) individuals. The age range of the study participants was 12–63 years. All anthropometric and metabolic parameters were measured for each participant via standard procedures and biochemical assays, respectively. The genetic variants were genotyped by allelic discrimination assays. The age- and gender-adjusted associations between the GRS and obesity-related anthropometric and metabolic measures were determined using linear regression analyses. The results showed that OW/OB individuals had significantly higher mean ranks of GRS than NW individuals. Moreover, a significant association of the GRS with obesity-related anthropometric traits was seen. However, the GRS did not appear to affect any obesity-related metabolic parameter. In conclusion, our findings indicate the combined effect of multiple genetic variants on the obesity-related anthropometric phenotypes in Pakistanis.
Subject terms: Genetics, Molecular biology
Introduction
Obesity is a multifactorial and complex metabolic disorder involving a chronic imbalance of energy homeostasis that has adverse implications for health such as dyslipidemia, arterial hypertension, coronary heart disease, type 2 diabetes mellitus, ovarian polycystosis, gallbladder lithiasis, sleep apnea syndrome, arthropathy, cerebral vasculopathy, and some neoplasms1. The substantially increasing worldwide prevalence of obesity has made it one of the major global public health concerns2. It is generally ascribed to unhealthy lifestyle choices or environmental factors but it is also known to have a strong genetic component. Thus, obesity is highly heritable and inherent genetic variations can confer augmented predisposition in some people while protection in others3, 4. In rare instances, genetic predisposition to obesity can be owing to a large-effect mutation that disrupts energy homeostasis5. Nevertheless, no such monogenic mutation can be indicated for the prevailing majority of severely obese people6–8. The genetic predisposition to obesity is but rather an outcome of the cumulative effects of several genetic variants with individually modest effects. This polygenic inheritance involving numerous common genetic variants has been reported to account for the majority of inherited predisposition to complex and common diseases in addition to obesity9–11. Therefore, it can be said that a single genetic variant can significantly affect the risk of disease occurrence in case of monogenic Mendelian disorders while multiple genetic variants (that individually play only a modest role in conferring disease risk) collectively make a considerable contribution in manifestation of complex traits and common disorders. In this context, the concept of genetic risk score (GRS) has emerged by which the cumulative small effect sizes of multiple genetic variants can be exploited to generate an overall score for predicting these traits and disorders. The GRS has been shown to provide reliable risk prediction for many complex genetic traits12. In particular, the remarkable potential of GRS for identifying individuals at a higher risk of developing obesity has been revealed13, 14.
The GRS is based on simple counts of disease-causing alleles. Generally, the GRS of any complex genetic trait can be computed by adding up risk alleles. Calculating a GRS by uniting information for multiple genetic variants offers a tool for examining genetic contributions in the manifestation of obesity in samples much smaller than are required for GWAS (genome-wide association studies)15, 16. Most GRS studies on obesity have been conducted on western populations so far14, 17. Thus at present, extending the scope of genetic studies to examine populations of other descents or under-represented populations is warranted18. Pakistani population is an under-represented population in this context. Pakistan is a South Asian country and its population offers many advantages in revealing the obesity etiology, which are attributable to its distinctive features including its recent nutritional transition, complex demographic history, diversity, endogamy, and consanguineous marriage practices resulting in a high rate of inbreeding, and the presence of large families19. Moreover, Pakistan has been recently ranked among the top 10 most obese countries in the world as per the Global Burden of Disease Study 201320. Therefore, the current study has been undertaken to compute the GRS based on five obesity-linked key loci including MC4R rs17782313, BDNF rs6265, FTO rs1421085, TMEM18 rs7561317, and NEGR1 rs2815752 in this at-risk and under-represented population. The aforementioned genetic variants were previously reported to be individually associated with overweight/obesity in large GWASs on western populations21, 22 as well as in a sample of Pakistani population23–26.
The FTO (fat mass and obesity-associated) gene is the first obesity-susceptibility locus identified by GWAS27, 28. The upregulation of FTO leads to increased fat mass and obesity possibly through hyperphagia and/or low energy expenditure29, 30. MC4R (melanocortin 4 receptor) and BDNF (brain-derived neurotrophic factor) play a crucial role in the central regulation of energy homeostasis via induction of satiety and increased energy expenditure31, 32. TMEM18 (transmembrane protein 18) has also been indicated to play a role in the central regulation of appetite and energy expenditure as germline loss of TMEM18 in mice resulted in increased body weight driven by increased food intake and aggravated by high-fat diet while selective overexpression of TMEM18 in the paraventricular nucleus of wild-type mice decreased food intake and also enhanced energy expenditure33. NEGR1 may affect body weight via influencing energy balance, fat production and transport, and the structure of brain areas involved in feeding behavior34–37. Thus, risk variants within or near the aforementioned genes, which either increase or decrease their expression and/or function can result in insatiable appetite and/or low energy expenditure; consequently, leading to weight gain and obesity.
Previously, we sought individual associations of the aforementioned five genetic variants with overweight/obesity and related anthropometric and metabolic traits whereas now in the current study we seek the association of the GRS based on all the aforementioned five genetic variants with the obesity-related anthropometric as well as metabolic measures in the same sample of Pakistani population.
Results
Sample description
The ages of the sample population ranged from 12 to 63 years. The total sample population was composed of 606 individuals including 270 females and 336 males. There were an equal number of males (n = 168) in both overweight/obese (OW/OB) and normal-weight (NW) groups. However, there were 138 and 132 females in OW/OB and NW groups, respectively.
Significant differences in study variables including GRS between OW/OB and NW Individuals
First, all anthropometric and metabolic parameters were compared between OW/OB and NW individuals. Anthropometric parameters included body weight, height, body mass index (BMI), waist circumference (WC), hip circumference (HC), skinfold thicknesses (SFTs), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), body fat percentage (%BF). Similarly, metabolic parameters encompassed systolic blood pressure (SBP), diastolic blood pressure (DBP), the product of triglycerides and glucose (TyG), fasting blood glucose (FBG), fasting insulin, homeostatic model assessment-insulin resistance (HOMA-IR), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very-low-density-lipoprotein cholesterol (VLDL-C), coronary risk index (CRI), atherogenic index (AI), triglyceride-to-HDL-C ratio (TG/HDL-C). All anthropometric and metabolic parameters except height, HDL-C, and CRI differed significantly between OW/OB and NW individuals being higher in OW/OB as compared with NW individuals (Table 1). Similarly, the mean ranks of GRS were found to differ significantly between OW/OB and NW individuals being higher in OW/OB as compared with NW individuals (Table 2).
Table 1.
Comparison of the obesity-related anthropometric and metabolic parameters between OW/OB and NW individuals.
| Parameters (unit of measurement) | Overweight/obese individuals | Normal-weight individuals | p value | q-value | ||
|---|---|---|---|---|---|---|
| Mean ± SD | Mean ranks | Mean ± SD | Mean ranks | |||
| Weight (Kg) | 89.01 ± 19.25 | 439.83 | 59.20 ± 7.91 | 164.45 | < 0.001 | < 0.001 |
| Height (cm) | 164.27 ± 9.36 | 296.39 | 164.10 ± 8.55 | 310.76 | 0.312 | 0.312 |
| BMI (Kg/m2) | 32.89 ± 6.07 | 453.44 | 21.70 ± 2.01 | 150.56 | < 0.001 | < 0.001 |
| WC (cm) | 110.73 ± 14.26 | 444.08 | 82.95 ± 8.24 | 160.11 | < 0.001 | < 0.001 |
| HC (cm) | 114.61 ± 12.02 | 440.34 | 94.89 ± 5.80 | 163.92 | < 0.001 | < 0.001 |
| WHR | 0.97 ± 0.06 | 405.91 | 0.87 ± 0.07 | 199.04 | < 0.001 | < 0.001 |
| WHtR | 0.99 ± 0.33 | 442.78 | 0.50 ± 0.05 | 161.43 | < 0.001 | < 0.001 |
| Biceps SFT (mm) | 19.21 ± 8.74 | 410.28 | 8.89 ± 4.94 | 194.58 | < 0.001 | < 0.001 |
| Triceps SFT (mm) | 31.36 ± 9.94 | 430.44 | 14.89 ± 6.74 | 174.02 | < 0.001 | < 0.001 |
| Sub-scapular SFT (mm) | 33.20 ± 11.18 | 425.03 | 17.26 ± 6.18 | 178.12 | < 0.001 | < 0.001 |
| Abdominal SFT (mm) | 47.26 ± 15.40 | 428.19 | 24.28 ± 9.36 | 176.32 | < 0.001 | < 0.001 |
| Thigh SFT (mm) | 47.11 ± 16.72 | 431.91 | 20.41 ± 9.10 | 172.52 | < 0.001 | < 0.001 |
| Supra-iliac SFT (mm) | 38.65 ± 14.83 | 422.04 | 19.13 ± 8.07 | 182.59 | < 0.001 | < 0.001 |
| % BF | 34.94 ± 6.19 | 437.13 | 20.34 ± 6.97 | 167.20 | < 0.001 | < 0.001 |
| SBP (mmHg) | 119.90 ± 14.93 | 340.85 | 113.40 ± 13.46 | 265.40 | < 0.001 | < 0.001 |
| DBP (mmHg) | 79.80 ± 11.05 | 342.52 | 74.51 ± 9.52 | 263.70 | < 0.001 | < 0.001 |
| TyG index | 8.74 ± 0.51 | 357.78 | 8.44 ± .49 | 248.14 | < 0.001 | < 0.001 |
| FBG (mg/dL) | 105.10 ± 24.50 | 329.17 | 99.51 ± 12.55 | 277.32 | < 0.001 | < 0.001 |
| Fasting insulin (µl U/mL) | 27.01 ± 14.49 | 366.18 | 18.83 ± 12.21 | 239.57 | < 0.001 | < 0.001 |
| HOMA-IR | 6.99 ± 3.95 | 368.39 | 4.76 ± 3.97 | 237.31 | < 0.001 | < 0.001 |
| TC (mg/dL) | 157.79 ± 39.26 | 328.59 | 145.87 ± 38.85 | 277.91 | < 0.001 | < 0.001 |
| TG (mg/dL) | 135.55 ± 75.42 | 353.42 | 104.48 ± 57.78 | 252.58 | < 0.001 | < 0.001 |
| HDL-C (mg/dL) | 30.974 ± 9.39 | 313.36 | 29.82 ± 9.17 | 293.45 | 0.161 | 0.161 |
| LDL-C (mg/dL) | 103.42 ± 37.09 | 362.64 | 79.51 ± 31.48 | 243.17 | < 0.001 | < 0.001 |
| LDL-C (mg/dL) | 27.00 ± 15.04 | 349.74 | 21.18 ± 11.41 | 255.16 | < 0.001 | < 0.001 |
| CRI | 5.46 ± 1.91 | 314.69 | 5.15 ± 1.52 | 292.08 | 0.122 | 0.131 |
| AI | 3.47 ± 1.26 | 351.10 | 2.81 ± 1.14 | 254.95 | < 0.001 | < 0.001 |
| TG/HDL-C | 4.72 ± 3.14 | 341.24 | 3.88 ± 2.98 | 265.00 | < 0.001 | < 0.001 |
OW/OB overweight/obese, NW normal-weight, BMI body mass index, WC waist circumference, HC hip circumference, WHR waist-to-hip ratio, WHtR waist-to-height ratio, SFT skinfold thickness, % BF body fat percentage, SBP systolic blood pressure, DBP diastolic blood pressure, TyG the product of triglycerides and glucose, FBG fasting blood glucose, HOMA-IR homeostatic model assessment-insulin resistance, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, VLDL-C very-low-density-lipoprotein cholesterol, CRI Coronary Risk Index, AI Atherogenic Index, TG/HDL-C triglyceride-to-HDL-C ratio, SD standard deviation, CI confidence interval, q-value corrected p value.
The comparison of the obesity-related anthropometric and metabolic parameters between overweight/obese and normal-weight individuals was determined by Mann–Whitney U test. The mean ± SD and mean ranks were calculated to show the difference of parameters between overweight/obese and normal-weight individuals. The analysis was corrected for multiple comparisons via the Benjamini–Hochberg method of false discovery rate (FDR) control. A p value < 0.05 was considered statistically significant. The significant p values are indicated in bold.
Table 2.
Comparison of GRS between overweight/obese and normal-weight individuals.
| GRS | OW/OB individuals (n = 306) | NW individuals (n = 300) | p value |
|---|---|---|---|
| Mean ranks | 322.66 | 283.96 | 0.005 |
| Minimum | 2 | 1 | |
| Maximum | 9 | 9 |
GRS genetic risk score, OW/OB overweight/obese, NW normal-weight.
The p value for GRS was calculated by the Mann–Whitney U test. The p value was considered significant and indicated in bold when p value < 0.05.
Allele frequencies and association of individual variants with overweight/obesity
The risk allele frequencies (RAFs) of all the variants are given in Table 3. The RAFs for all the variants except rs6265 were higher in the OW/OB as compared to NW individuals; however, this difference was found to be statistically significant for the TMEM18 rs7561317 only. Consequently, the multinomial logistic regression analysis also revealed a significant association of only rs7561317 with overweight/obesity (Table 3).
Table 3.
Comparison of RAFs of the variants between OW/OB and NW individuals along with the association of the variants with overweight/obesity.
| Gene/locus | Variant | Variant location | Risk allele | RAFs OW/OB individuals | RAFs NW individuals | OR (95% CI) | p value |
|---|---|---|---|---|---|---|---|
| MC4R | rs17782313 | Intergenic | C | 43.8% | 40.3% | 1.144 (0.911–1.437) | 0.246 |
| BDNF | rs6265 | Missense | A | 19.8% | 19.8% | 0.995 (0.751–1.318) | 0.972 |
| FTO | rs1421085 | Intron | C | 33.8% | 30.8% | 1.151 (0.902–1.471) | 0.259 |
| TMEM18 | rs7561317 | Intergenic | G | 87.9% | 81.8% | 1.571 (1.146–2.153) | 0.005 |
| NEGR1 | rs2815752 | Intron | A | 66.8% | 64.3% | 1.137 (0.899–1.483) | 0.284 |
OW/OB overweight/obese, NW normal-weight, RAFs risk allele frequencies, OR odds ratio, CI confidence interval.
The data represents risk allele frequencies (RAFs) in overweight/obese and normal-weight individuals along with odds ratios and confidence intervals in parenthesis. Association was tested using multinomial logistic regression assuming an additive model. The analysis was performed by adjusting age and gender. An adjusted p value < 0.05 was considered significant. The significant p value is indicated in bold.
Association of the GRS with obesity-related anthropometric parameters
A significant association of the GRS with nearly all the anthropometric variables such as body weight, BMI, WC, HC, WHR, WHtR, SFTs (biceps, triceps, supra-iliac, abdominal, thigh, and sub-scapular), and %BF was observed (Table 4). The strongest association of the GRS was seen with augmented body weight, BMI, WC, and WHtR (p = 0.007) followed by enhanced HC, biceps and thigh SFTs (p = 0.008), sub-scapular SFT (p = 0.018), WHR, triceps SFT and % BF (p = 0.02), and abdominal and supra-iliac SFTs (p = 0.04).
Table 4.
Association of the genetic risk score with obesity-related anthropometric variables.
| Parameters (unit of measurement) | β (S.E.) | 95% CI | p value | q-value |
|---|---|---|---|---|
| Weight (Kg) | 1.863 (0.574) | 0.736–2.989 | 0.001 | 0.007 |
| Height (cm) | − 0.230 (0.270) | − 0.760 to 0.300 | 0.395 | 0.395 |
| BMI (Kg/m2) | 0.691 (0.203) | 0.292–1.089 | 0.001 | 0.007 |
| WC (cm) | 1.651 (0.519) | 0.633–2.670 | 0.002 | 0.007 |
| HC (cm) | 1.188 (0.403) | 0.396–1.980 | 0.003 | 0.008 |
| WHR | 0.006 (0.002) | 0.001–0.010 | 0.016 | 0.021 |
| WHtR | 0.029 (0.009) | 0.010–0.047 | 0.002 | 0.007 |
| Biceps SFT (mm) | 0.682 (0.233) | 0.224–1.140 | 0.004 | 0.008 |
| Triceps SFT (mm) | 0.798 (0.332) | 0.145–1.450 | 0.017 | 0.021 |
| Sub-scapular SFT (mm) | 0.879 (0.339) | 0.213–1.545 | 0.010 | 0.018 |
| Abdominal SFT (mm) | 1.015 (0.481) | 0.070–1.960 | 0.035 | 0.041 |
| Thigh SFT (mm) | 1.558 (0.534) | 0.510–2.606 | 0.004 | 0.008 |
| Supra-iliac SFT (mm) | 0.858 (0.421) | 0.031–1.685 | 0.042 | 0.045 |
| % BF | 0.689 (0.275) | 0.148–1.229 | 0.013 | 0.020 |
BMI body mass index, WC waist circumference, HC hip circumference, WHR waist-to-hip ratio, WHtR waist-to-height ratio, SFT skinfold thickness, % BF body fat percentage, SE standard error, CI confidence interval, q-value corrected p value.
The association of the genetic risk score with anthropometric traits was determined by linear regression. Effect size (β) and 95% confidence intervals were computed to seek rise or fall in the selected parameter per each risk allele increase. All association analyses were adjusted for age and gender and corrected for multiple comparisons via the Benjamini–Hochberg method. A p value < 0.05 was considered statistically significant. The significant p values are indicated in bold.
Association of the GRS with obesity-related metabolic traits
No significant association of the GRS with any of the obesity-related metabolic variables such as SBP, DBP, TyG, FBG, fasting insulin, HOMA-IR, TC, TG, HDL-C, LDL-C, VLDL-C, CRI, AI, and TG/HDL-C was seen (Table 5).
Table 5.
Association of the genetic risk score with obesity-related metabolic traits.
| Parameters (unit of measurement) | β (S.E.) | 95% CI | p value | q-value |
|---|---|---|---|---|
| SBP (mmHg) | 0.757 (0.382) | 0.006–1.508 | 0.048 | 0.168 |
| DBP (mmHg) | 0.565 (0.278) | 0.019–1.112 | 0.043 | 0.168 |
| TyG index | − 0.030 (0.017) | − 0.063 to 0.004 | 0.079 | 0.184 |
| FBG (mg/dL) | 0.308 (0.552) | − 0.776 to 1.392 | 0.577 | 0.809 |
| Fasting insulin (µL U/mL) | − 0.122 (0.400) | − 0.908 to 0.663 | 0.760 | 0.819 |
| HOMA-IR | − 0.017 (0.116) | − 0.246 to 0.212 | 0.883 | 0.883 |
| TC (mg/dL) | − 0.939 (1.131) | − 3.161 to 1.282 | 0.407 | 0.633 |
| TG (mg/dL−1) | − 3.899 (1.906) | − 7.642 to − 0.156 | 0.041 | 0.168 |
| HDL-C (mg/dL) | 0.112 (0.265) | − 0.408 to 0.632 | 0.673 | 0.819 |
| LDL-C (mg/dL) | − 1.428 (1.031) | − 3.452 to 0.595 | 0.166 | 0.326 |
| VLDL-C (mg/dL) | − 0.746 (0.376) | − 1.485 to − 0.007 | 0.048 | 0.168 |
| CRI | − 0.015 (0.049) | − 0.111 to 0.080 | 0.753 | 0.819 |
| AI | − 0.045 (0.034) | − 0.112 to 0.022 | 0.186 | 0.326 |
| TG/HDL-C | − 0.155 (0.084) | − 0.319 to 0.009 | 0.064 | 0.179 |
SBP systolic blood pressure, DBP diastolic blood pressure, TyG the product of triglycerides and glucose, FBG fasting blood glucose, HOMA-IR homeostatic model assessment-insulin resistance, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, VLDL-C very-low-density-lipoprotein cholesterol, CRI Coronary Risk Index, AI Atherogenic Index, TG/HDL-C triglyceride-to-HDL-C ratio, SE standard error, CI confidence interval, q-value corrected p value.
The association of the genetic risk score with metabolic traits was determined by linear regression. Effect size (β) and 95% confidence intervals were computed to seek rise or fall in the selected parameter per each risk allele increase. All association analyses were adjusted for age and gender and corrected for multiple comparisons via the Benjamini–Hochberg method. A p value < 0.05 was considered statistically significant.
Discussion
Overweight/obesity is a multifactorial metabolic disorder having a complex genetic background 38. In this context, the estimated heritability of obesity ranges from 40 to 70%39. Numerous candidate gene studies and GWAS have discovered several obesity-related genetic variants40, however, the additive effect of these variants on obesity risk has been reported in very few studies. In particular, the studies for exploring the combined effect of multiple genetic variants on the risk of obesity and related traits regarding Pakistani population are in their infancy. As common obesity has a polygenic inheritance, the assessment of cumulative effect based on GRS is very crucial to fully comprehend the components of genetic architecture and physiopathology of obesity. The striking potential of GRS for identifying individuals at a higher risk of developing overweight/obesity has been revealed in this regard13, 14.
The rs1421085 of the FTO gene (T > C) is anticipated as the causal variant for overweight/obesity and it has been linked with a higher total energy intake and more eating episodes per day41, 42. The obesity-increasing effect of FTO rs1421085 has been shown to disrupt ARID5B-mediated repression of IRX3 and IRX5 expression in pre-adipocytes that in turn leads to the excessive accumulation of triglycerides, increased adipocytes size, reduced mitochondrial oxidative capacity, and reduced white adipocytes browning, resulting in reduced mitochondrial thermogenesis43. The variant rs17782313 (T > C) located 188 kb downstream of the MC4R gene is strongly linked with obesity and the disruption of the transcriptional control of MC4R has been proposed as the likely mechanism of this variant44. Likewise, the rs6265 variant (G > A) in the coding region of the BDNF gene that involves Valine to Methionine substitution at the 66th amino acid position (Val66Met) of the N-terminal domain of pro-BDNF has also been linked with obesity. The intracellular trafficking and depolarization-induced release of BDNF are hampered due to this risk variant (rs6265)45, 46. The rs7561317, located about 22 kb downstream of TMEM18 is also an obesity-associated genetic variant that may diminish the expression of the TMEM18 gene and thus play a role in the manifestation of obesity33, 47. The rs2815752 variant (G > A) positioned 20 kb upstream of the NEGR1 gene presumably decreasing its expression is linked with increased risk of obesity48.
The current study computes the GRS based on the above-discussed five obesity-linked key loci (FTO rs1421085, MC4R rs17782313, BDNF rs6265, TMEM18 rs7561317, and NEGR1 rs2815752), which were previously found to be individually associated with obesity and related anthropometric and metabolic measures in the same sample of Pakistani population23–26. In our previous studies, the aforementioned individual associations were sought using multiple genetic models and in the case of obtaining association in more than one model, the h-index was calculated to indicate the relevant mode of inheritance (such as dominant, recessive, or over-dominant). Also, associations of the two variants FTO rs142108524 and TMEM18 rs756131725 were obtained without gender stratification while those of the other two namely MC4R rs1778231323 and NEGR1 rs281575226 were observed after gender stratification in females only. Moreover, no association was found for BDNF rs626549. However, in the current study, we used a single additive model for simultaneously encompassing all the aforementioned five different genetic variants in the analysis to compute GRS for obesity-related anthropometric and metabolic phenotypes. Moreover, the sample population was not stratified based on gender in the current study. Therefore, the use of an additive model and non-stratification of the sample population might be the possible reasons that only rs7561317 was found to be associated with the overweight/obesity, when before computing GRS, individual associations of the aforementioned variants with obesity were sought in the current study.
The current study has been undertaken to determine the susceptibility when the combined effects of the above-mentioned five variants are considered because common obesity has a polygenic inheritance as indicated before. Moreover, the cumulative effect of these five variants for the increased risk of obesity has not been studied before in the Pakistani population. In the present study, the GRS based on the aforementioned five genetic variants appeared to be significantly associated with the obesity-related anthropometric parameters such as body weight, BMI, WC, HC, WHR, WHtR, SFTs, and BF% in a sample of Pakistanis regardless of age and gender. This indicates that individuals with high GRS may be more predisposed to the development of overweight/obesity. It must be noted that four out of five genetic variants could not exhibit any significant association with overweight or obesity when associations for individual variants were sought in the current study. However, the significant association of GRS based on a count of risk-associated alleles across a panel of five aforementioned genetic variants was observed, which point to the benefit of identifying a significant association based on the additive count of multiple genetic variants that individually may or may not appear to exhibit a significant association with the risk of overweight/obesity in a sample population. This implies that the use of GRS is comparatively a better approach to estimate the genetic risk of overweight/obesity based on different multiple common risk variants rather than individual risk variants especially when the sample size is not very large.
Previously, two studies also reported a significant association of GRS based on obesity-associated genetic variants with the increased risk of being obese in Pakistanis50, 51. However, the GRS in these aforementioned two studies were based on different sets of genetic variants, which differed not only between these studies but also differed with our study. This indicated the additive power of GRS over an individual variant because common obesity has a polygenic inheritance implying that various obesity-associated genetic variants act in concert to modulate the bodyweight52. Our and the two aforementioned studies50, 51 can be considered to create a panel of genetic variants for estimating the risk of an individual for developing obesity. The association of the GRS with almost all anthropometric traits (body weight, BMI, WC, HC, WHR, WHtR, skinfold thicknesses, and %BF) in our study showed the additive effect of these variants on fat distribution resulting in increased body weight. It is important to note that WC and WHtR are the main determinants of abdominal obesity, cardiovascular diseases, and increased mortality risk53–56. Thus, the higher GRS (constructed in our study) may escalate the risk of cardiovascular disease and mortality via increasing WC and WHtR.
An interesting and important aspect of the current study is that we not only computed and sought the association of the GRS with the obesity-related anthropometric measures but also with obesity-related metabolic measures. Nevertheless, the GRS in the current study showed a lack of association with all metabolic traits including the parameters related to glucose and lipid metabolism, and blood pressure. Likewise, none of the aforementioned five genetic variants in our previous studies individually showed a significant association with any of the obesity-related metabolic traits in the same sample of the Pakistani population23–26, 49. However, it must be noted that the values of nearly all the metabolic parameters (like anthropometric variables) were found significantly higher in overweight/obese individuals as compared to normal-weight individuals. Moreover, the GRS computed in our study was based on the genetic variants mainly involved in energy homeostasis and body weight regulation via regulating appetite and energy expenditure as already mentioned in the introduction section. Thus, it can be said that these variants may indirectly influence metabolism via increasing BMI and other obesity-related anthropometric measures.
In the end, it can be concluded that the cumulative or combined effect based on GRS may be valuable for better comprehension of the genetic susceptibility to obesity and may help researchers to better understand trait biology.
Material and methods
Study design, setting, and ethics
It was an analytical observational study based on a case–control design and was performed at Dr. Panjwani Center for Molecular Medicine and Drug Research (PCMD), International Center for Chemical and Biological Sciences (ICCBS), University of Karachi (UoK), Pakistan. All procedures performed in the study involving human participants were in accordance with the ethical standards of the Independent Ethics Committee (IEC) of the ICCBS and Advanced Studies and Research Board (ASRB) of the University of Karachi, Pakistan, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Independent Ethics Committee (IEC) of the ICCBS and Advanced Studies and Research Board (ASRB) of the University of Karachi.
Sample population and phenotypic traits
The study involved a total of 606 participants including 306 overweight/obese (OW/OB) and 300 normal-weight (NW) individuals. The participants were recruited from the general population of Karachi, a metropolitan city of Pakistan, including universities and colleges of the city using the simple random sampling without replacement technique. However, all the participants were not permanent residents of the city. All the participants or their parents/guardians (in the case of children or adolescents) signed the written informed consent before participation in the study. The demographic information regarding the recruited participants was acquired through a questionnaire. The body mass index (BMI) reference ranges for adults were considered according to World Health Organization (WHO), whereas for children/adolescents, BMI reference ranges were considered according to growth charts of the Center for Disease Control and Prevention (CDC). However, the individuals with a history of taking drugs such as antidepressants, phenothiazine, and steroids, etc., and having any type of endocrinological disorder were not included in the study. Blood pressure (BP) was measured from the right-upper arm according to the standard procedure by using a mercury column sphygmomanometer (Certeza medical, Germany) while the individual was sitting comfortably. The BP of each individual was measured twice to calculate the average value. The body weight was measured in kilograms (kg) with the precision of up to 0.1 kg by using a mechanical weighing balance (Seca 755, Germany). Moreover, the body height was measured in centimeters (cm) with the precision of up to 0.1 cm by using a portable stadiometer (Seca 214, Germany). Both measurements were assessed without shoes and in light clothes. To calculate BMI, height was converted into meters (m) and then the value of weight (kg) was divided by the value of height in the square (m2). The waist circumference (WC) and hip circumference (HC) were measured with a non-elastic measuring tape. The skinfold thicknesses (SFTs) such as biceps, triceps, suprailiac, abdomen, thigh, and sub-scapular were measured in millimeters (mm) by using a skin-fold caliper (Slim Guide, MI, USA). All the measurements were taken thrice to compute the average value for each SFT. The waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR) were calculated using the values of WC, HC, and height. The body fat percentage (%BF) was computed using the sum of SFTs by employing gender-specific formulae57. The fasting (8–12 h) blood samples from each participant were collected in two separate vacutainer tubes for subsequent serum and DNA isolation. Fasting blood glucose was measured using a glucose monitoring system (Abbott, UK) while fasting insulin levels were measured by ELISA (enzyme-linked immunosorbent assay) using a commercial kit (DIA source, Belgium). The values of fasting glucose and insulin were used to calculate homeostatic model assessment-insulin resistance (HOMA-IR) by applying relevant formula58. Moreover, lipid parameters (total cholesterol, triglycerides, HDL-C, and LDL-C) were determined on a chemistry analyzer (Hitachi 902, Japan) by consuming commercial kits (Merck, Germany) based on enzymatic endpoint assays. The values of triglycerides were divided by 5 to calculate VLDL-C. Also, coronary risk index (CRI), atherogenic index (AI), triglyceride-to-HDL-C ratio (TG/HDL-C) were calculated59. Furthermore, the product of triglyceride and glucose (TyG) index was also computed60.
DNA extraction and genotyping
DNA was extracted from the collected blood samples by the spin column method consuming commercially available kits (Bio Basic, Canada). The genetic variants (MC4R rs17782313, BDNF rs6265, FTO rs1421085, TMEM18 rs7561317, and NEGR1 rs2815752) were genotyped using TaqMan allelic discrimination assays (assay ID of the rs17782313: C__32 667060_10, cat. # 4351376, ABI, Foster City, CA, USA; assay ID of the rs6265: C__11592758_10, cat. # 4351379, ABI, Foster City, CA, USA; assay ID of the rs1421085: C__8917103_10, cat. # 4351379, ABI, Foster City, CA, USA; assay ID of the rs7561317: C__32 667 060_10, cat # 4351376, ABI, Foster City, CA, USA; assay ID of rs2815752: C__26668839_10, cat # 4351379, ABI, Foster City, CA) containing specific primers and probes and TaqMan master mix (Applied Biosystems, USA) on a real-time PCR System (ABI 7500, USA). Every batch of PCR experiments consisted of positive control for each genotype of all the variants as well as two negative controls (no template controls). 20% of the samples were genotyped twice for reproducibility.
Statistical analysis
All statistical analyses were performed utilizing the Statistical Package for Social Sciences version 21 (SPSS, IBM statistics). Hardy–Weinberg Equilibrium (HWE) test was applied to determine whether the genotypic distributions of all the variants were in HWE. The Shapiro–Wilk test was availed to check the normality of the data. The obesity-associated risk alleles of MC4R rs17782313, BDNF rs6265, FTO rs1421085, TMEM18 rs7561317, and NEGR1 rs2815752 were C, A, C, G, and A, respectively. The homozygous wild type (non-risk), heterozygous (risk), and homozygous mutant (risk) genotypes were coded as 0, 1, and 2, respectively. The GRS was constructed by summing the number of risk alleles (0, 1, and 2) of the aforesaid genetic variants. Since we included five bi-allelic variants, an individual may have a minimum of 0 and a maximum of 10 risk alleles. However, none of the individuals was found to have either 0 or 10 risk alleles. The study individuals were found to have a minimum of 1 and a maximum of 9 risk alleles. The GRS and the other continuous variables were compared between overweight/obese and normal-weight individuals by employing Mann–Whitney U test. Allelic frequencies of all the variants were calculated by direct count. The association of each variant with overweight/obesity was sought by assuming an additive model. Multinomial logistic regression was applied and the odds ratio (OR) along with 95% confidence intervals (CI) was calculated to predict the overweight/obesity risk associated with each variant as well as with GRS. The association of GRS with obesity-related anthropometric and metabolic parameters was determined by linear regression. For conformity to the linearity assumption of the linear regression, all non-normal data were transformed into normal distribution through a rank-based inverse normal transformation. The effect sizes (β) along with 95% CI were determined for all anthropometric and metabolic parameters. All analyses were adjusted for confounders such as age and gender and also corrected for multiple comparisons by the Benjamin-Hochberg method as per requirement61. A p value < 0.05 was considered statistically significant for all analyses.
Acknowledgements
The authors are thankful to Ms. Soma Rahmani, Mr. Saad Mirza, Ms. Ayesha Sultana, and Ms. Maha Mobin for their contribution to genotyping. This study was funded by a research grant from the Higher Education Commission (HEC) of Pakistan (Ref. No. 5740/Sindh/NRPU/R&D/HEC/2016); and a recurring grant from the International Center for Chemical and Biological Sciences (ICCBS) (Grant No. Recurring grant No. 0808-2015), University of Karachi, Pakistan. The funding bodies did not participate in the study design, sample collection, data analysis and interpretation, and manuscript writing.
Author contributions
S.R. conceived and designed the study, acquired funding, contributed to data collection, analysis, and interpretation of the data, and wrote and critically revised the manuscript for important intellectual content. A.A.B. performed the experiments, contributed to data collection, analysis, and interpretation of the data, and wrote the manuscript. Both authors read and approved the final manuscript.
Data availability
All data generated or analyzed during this study are included in this published article.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.De Lorenzo A, et al. Why primary obesity is a disease? J. Transl. Med. 2019;17:169. doi: 10.1186/s12967-019-1919-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33:673–689. doi: 10.1007/s40273-014-0243-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Elks CE, et al. Variability in the heritability of body mass index: a systematic review and meta-regression. Front. Endocrinol. (Lausanne) 2012;3:29. doi: 10.3389/fendo.2012.00029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Yang J, et al. Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index. Nat. Genet. 2015;47:1114–1120. doi: 10.1038/ng.3390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Barsh GS, Farooqi IS, O'Rahilly S. Genetics of body-weight regulation. Nature. 2000;404:644–651. doi: 10.1038/35007519. [DOI] [PubMed] [Google Scholar]
- 6.Vaisse C, et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J. Clin. Invest. 2000;106:253–262. doi: 10.1172/jci9238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Larsen LH, et al. Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity. J. Clin. Endocrinol. Metab. 2005;90:219–224. doi: 10.1210/jc.2004-0497. [DOI] [PubMed] [Google Scholar]
- 8.Stutzmann F, et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes. 2008;57:2511–2518. doi: 10.2337/db08-0153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Yang J, et al. Genome partitioning of genetic variation for complex traits using common SNPs. Nat. Genet. 2011;43:519–525. doi: 10.1038/ng.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Golan D, Lander ES, Rosset S. Measuring missing heritability: inferring the contribution of common variants. Proc. Natl. Acad. Sci. 2014;111:E5272–E5281. doi: 10.1073/pnas.1419064111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Zhu Z, et al. Dominance genetic variation contributes little to the missing heritability for human complex traits. Am. J. Hum. Genet. 2015;96:377–385. doi: 10.1016/j.ajhg.2015.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 2018;50:1219–1224. doi: 10.1038/s41588-018-0183-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Khera AV, et al. Polygenic prediction of weight and obesity trajectories from birth to adulthood. Cell. 2019;177:587–596.e589. doi: 10.1016/j.cell.2019.03.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Hung C-F, et al. A genetic risk score combining 32 SNPs is associated with body mass index and improves obesity prediction in people with major depressive disorder. BMC Med. 2015;13:86. doi: 10.1186/s12916-015-0334-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Plomin R, Haworth CMA, Davis OSP. Common disorders are quantitative traits. Nat. Rev. Genet. 2009;10:872–878. doi: 10.1038/nrg2670. [DOI] [PubMed] [Google Scholar]
- 16.Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet. 2013;9:e1003348. doi: 10.1371/journal.pgen.1003348. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Belsky DW, et al. Development and evaluation of a genetic risk score for obesity. Biodemogr. Soc. Biol. 2013;59:85–100. doi: 10.1080/19485565.2013.774628. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Duncan L, et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat. Commun. 2019;10:3328. doi: 10.1038/s41467-019-11112-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Pigeyre M, Saqlain M, Turcotte M, Raja GK, Meyre D. Obesity genetics: insights from the Pakistani population. Obes. Rev. 2018;19:364–380. doi: 10.1111/obr.12644. [DOI] [PubMed] [Google Scholar]
- 20.Ng M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–781. doi: 10.1016/s0140-6736(14)60460-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Yengo L, et al. Meta-analysis of genome-wide association studies for height and body mass index in ∼700000 individuals of European ancestry. Hum. Mol. Genet. 2018;27:3641–3649. doi: 10.1093/hmg/ddy271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Turcot V, et al. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nat. Genet. 2018;50:26–41. doi: 10.1038/s41588-017-0011-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Rana S, Rahmani S, Mirza S. MC4R variant rs17782313 and manifestation of obese phenotype in Pakistani females. RSC Adv. 2018;8:16957–16972. doi: 10.1039/C8RA00695D. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Rana S, Bhatti AA. Association and interaction of the FTO rs1421085 with overweight/obesity in a sample of Pakistani individuals. Eat. Weight Disord. 2020;25:1321–1332. doi: 10.1007/s40519-019-00765-x. [DOI] [PubMed] [Google Scholar]
- 25.Rana S, Sultana A. Association of the variant rs7561317 downstream of the TMEM18 gene with overweight/obesity and related anthropometric traits in a sample of Pakistani population. Biochem. Genet. 2020;58:257–278. doi: 10.1007/s10528-019-09940-2. [DOI] [PubMed] [Google Scholar]
- 26.Rana S, Mobin M. Association of the NEGR1 rs2815752 with obesity and related traits in Pakistani females. Upsala J. Med. Sci. 2020;125:226–234. doi: 10.1080/03009734.2020.1756996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Frayling TM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to child hood and adult obesity. Science (New York, N.Y.) 2007;316:889–894. doi: 10.1126/science.1141634. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Scuteri A, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet. 2007;3:e115. doi: 10.1371/journal.pgen.0030115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Church C, et al. Overexpression of Fto leads to increased food intake and results in obesity. Nat. Genet. 2010;42:1086–1092. doi: 10.1038/ng.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Fischer J, et al. Inactivation of the Fto gene protects from obesity. Nature. 2009;458:894–898. doi: 10.1038/nature07848. [DOI] [PubMed] [Google Scholar]
- 31.Krashes MJ, Lowell BB, Garfield AS. Melanocortin-4 receptor-regulated energy homeostasis. Nat. Neurosci. 2016;19:206–219. doi: 10.1038/nn.4202. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Xu B, Xie X. Neurotrophic factor control of satiety and body weight. Nat. Rev. Neurosci. 2016;17:282–292. doi: 10.1038/nrn.2016.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Larder R, et al. Obesity-associated gene TMEM18 has a role in the central control of appetite and body weight regulation. Proc. Natl. Acad. Sci. U.S.A. 2017;114:9421–9426. doi: 10.1073/pnas.1707310114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Boender AJ, van Gestel MA, Garner KM, Luijendijk MCM, Adan RAH. The obesity-associated gene Negr1 regulates aspects of energy balance in rat hypothalamic areas. Physiol. Rep. 2014;2:e12083. doi: 10.14814/phy2.12083. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Lee AWS, et al. Functional inactivation of the genome-wide association study obesity gene neuronal growth regulator 1 in mice causes a body mass phenotype. PLoS ONE. 2012;7:e41537–e41537. doi: 10.1371/journal.pone.0041537. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Kim H, et al. The new obesity-associated protein, neuronal growth regulator 1 (NEGR1), is implicated in Niemann–Pick disease Type C (NPC2)-mediated cholesterol trafficking. Biochem. Biophys. Res. Commun. 2017;482:1367–1374. doi: 10.1016/j.bbrc.2016.12.043. [DOI] [PubMed] [Google Scholar]
- 37.Joo Y, Kim H, Lee S, Lee S. Neuronal growth regulator 1-deficient mice show increased adiposity and decreased muscle mass. Int. J. Obes. 2019;2005(43):1769–1782. doi: 10.1038/s41366-019-0376-2. [DOI] [PubMed] [Google Scholar]
- 38.Herrera BM, Lindgren CM. The genetics of obesity. Curr. Diab. Rep. 2010;10:498–505. doi: 10.1007/s11892-010-0153-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Lobstein T, McPherson K. Nothing new in UK's strategy on childhood obesity. Lancet. 2016;388:853–854. doi: 10.1016/s0140-6736(16)31471-4. [DOI] [PubMed] [Google Scholar]
- 40.Pigeyre M, Yazdi FT, Kaur Y, Meyre D. Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin. Sci. (Lond.) 2016;130:943–986. doi: 10.1042/cs20160136. [DOI] [PubMed] [Google Scholar]
- 41.Harbron J, van der Merwe L, Zaahl MG, Kotze MJ, Senekal M. Fat mass and obesity-associated (FTO) gene polymorphisms are associated with physical activity, food intake, eating behaviors, psychological health, and modeled change in body mass index in overweight/obese Caucasian adults. Nutrients. 2014;6:3130–3152. doi: 10.3390/nu6083130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.McCaffery JM, et al. Obesity susceptibility loci and dietary intake in the look AHEAD trial. Am. J. Clin. Nutr. 2012;95:1477–1486. doi: 10.3945/ajcn.111.026955. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Claussnitzer M, et al. FTO obesity variant circuitry and adipocyte browning in humans. N. Engl. J. Med. 2015;373:895–907. doi: 10.1056/NEJMoa1502214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Loos RJ, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat. Genet. 2008;40:768–775. doi: 10.1038/ng.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Egan MF, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257–269. doi: 10.1016/s0092-8674(03)00035-7. [DOI] [PubMed] [Google Scholar]
- 46.Chen Z-Y, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J. Neurosci. 2004;24:4401–4411. doi: 10.1523/JNEUROSCI.0348-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Thorleifsson G, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat. Genet. 2009;41:18–24. doi: 10.1038/ng.274. [DOI] [PubMed] [Google Scholar]
- 48.Jarick I, et al. Novel common copy number variation for early onset extreme obesity on chromosome 11q11 identified by a genome-wide analysis. Hum. Mol. Genet. 2011;20:840–852. doi: 10.1093/hmg/ddq518. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Rana S, Mirza S, Rahmani S. The BDNF rs6265 variant may interact with overweight and obesity to influence obesity-related physical, metabolic and behavioural traits in Pakistani individuals. Ann. Hum. Biol. 2018;45:496–505. doi: 10.1080/03014460.2018.1561947. [DOI] [PubMed] [Google Scholar]
- 50.Shabana, Shahid SU, Hasnain S. Use of a gene score of multiple low-modest effect size variants can predict the risk of obesity better than the individual SNPs. Lipids Health Dis. 2018;17:155–155. doi: 10.1186/s12944-018-0806-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Ahmad S, et al. Physical activity, smoking, and genetic predisposition to obesity in people from Pakistan: the PROMIS study. BMC Med. Genet. 2015;16:114. doi: 10.1186/s12881-015-0259-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Hinney A, Vogel CIG, Hebebrand J. From monogenic to polygenic obesity: recent advances. Eur. Child Adolesc. Psychiatry. 2010;19:297–310. doi: 10.1007/s00787-010-0096-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Shen S, et al. Waist-to-height ratio is an effective indicator for comprehensive cardiovascular health. Sci. Rep. 2017;7:43046. doi: 10.1038/srep43046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Zhu S, et al. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. Am. J. Clin. Nutr. 2002;76:743–749. doi: 10.1093/ajcn/76.4.743. [DOI] [PubMed] [Google Scholar]
- 55.Hsieh SD, Yoshinaga H, Muto T. Waist-to-height ratio, a simple and practical index for assessing central fat distribution and metabolic risk in Japanese men and women. Int. J. Obes. Relat. Metab. Disord. 2003;27:610–616. doi: 10.1038/sj.ijo.0802259. [DOI] [PubMed] [Google Scholar]
- 56.Ashwell M, Mayhew L, Richardson J, Rickayzen B. Waist-to-height ratio is more predictive of years of life lost than body mass index. PLoS ONE. 2014;9:e103483. doi: 10.1371/journal.pone.0103483. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Jackson AS, Pollock ML. Practical assessment of body composition. Phys. Sportsmed. 1985;13:76–90. doi: 10.1080/00913847.1985.11708790. [DOI] [PubMed] [Google Scholar]
- 58.Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883. [DOI] [PubMed] [Google Scholar]
- 59.Kazemi T, Hajihosseini M, Moossavi M, Hemmati M, Ziaee M. Cardiovascular risk factors and atherogenic indices in an Iranian population: Birjand East of Iran. Clin. Med. Insights Cardiol. 2018 doi: 10.1177/1179546818759286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab. Syndr. Relat. Disord. 2008;6:299–304. doi: 10.1089/met.2008.0034. [DOI] [PubMed] [Google Scholar]
- 61.Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.) 1995;57:289–300. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data generated or analyzed during this study are included in this published article.
